What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to bargain from Cathie Wood’s banal portfolio. CRISPR made up astir 3.8% of ARK Investment’s disclosed equity portfolio astatine third-quarter-end, with a presumption valued astatine astir $634 million. ARK decreased its vulnerability somewhat successful Q3, reducing its holdings from 10.18 cardinal to 9.79 cardinal shares.

As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately affirmative opinion, with 60% analysts covering it having a Buy oregon equivalent rating. With a statement 1-year median terms people of $80, the banal has astir a 50% upside.

On November 12, Citi expert Yigal Nochomovitz reaffirmed his bullish stance connected CRISPR Therapeutics AG (NASDAQ:CRSP) with a Buy standing but lowered his terms from $87 to $77.

This enactment came intimately aft the institution reported its Q3 results connected November 10 and announced affirmative signifier 1 objective information for CTX310 connected November 8. CTX310 is an investigational gene-editing therapy that targets the ANGPTL3 cistron to perchance little triglycerides (TG) and low-density lipoprotein (LDL) cholesterin successful patients with terrible oregon refractory dyslipidemia. This advancement paves the mode for the institution to capitalize connected opportunities successful cardiovascular illness prevention, potentially.

On the value of the affirmative proceedings result, Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), stated:

“The work and presumption of these Phase 1 results people an important milestone for CRISPR Therapeutics and for the tract of successful vivo cistron editing. For the archetypal time, we’ve shown that a single-course successful vivo CRISPR attraction tin safely and durably little ANGPTL3, starring to clinically meaningful reductions successful triglycerides and LDL. These information supply beardown enactment for continued advancement of CTX310 and our broader cardiovascular gene-editing portfolio.”

In its Q3 2025 results, the company’s nett nonaccomplishment widened to $106.4 cardinal from $85.9 cardinal successful Q3 2024, driven by higher collaboration expenses. However, the equilibrium expanse remains robust with currency and currency equivalents of $1.94 cardinal arsenic of the extremity of September. The institution besides reported coagulated advancement since the motorboat of its sickle compartment illness and beta-thalassemia therapy CASGEVY.

CRISPR Therapeutics AG (NASDAQ:CRSP) is simply a starring cistron editing institution focused connected processing transformative medicines for superior diseases.

While we admit the imaginable of CRSP arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.